GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Gross Profit

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Gross Profit : $86.10 Mil (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Gross Profit?

Adamas Pharmaceuticals's gross profit for the three months ended in Sep. 2021 was $25.32 Mil. Adamas Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2021 was $86.10 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Adamas Pharmaceuticals's gross profit for the three months ended in Sep. 2021 was $25.32 Mil. Adamas Pharmaceuticals's Revenue for the three months ended in Sep. 2021 was $25.90 Mil. Therefore, Adamas Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2021 was 97.78%.

Adamas Pharmaceuticals had a gross margin of 97.78% for the quarter that ended in Sep. 2021 => Durable competitive advantage

During the past 9 years, the highest Gross Margin % of Adamas Pharmaceuticals was 98.14%. The lowest was 95.48%. And the median was 97.14%.


Adamas Pharmaceuticals Gross Profit Historical Data

The historical data trend for Adamas Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals Gross Profit Chart

Adamas Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross Profit
Get a 7-Day Free Trial Premium Member Only 0.57 0.55 33.41 52.17 72.42

Adamas Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.69 20.41 18.93 21.45 25.32

Competitive Comparison of Adamas Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adamas Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Adamas Pharmaceuticals's Gross Profit falls into.



Adamas Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Adamas Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )=Revenue - Cost of Goods Sold
=74.461 - 2.038
=72.42

Adamas Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2021 is calculated as

Gross Profit (Q: Sep. 2021 )=Revenue - Cost of Goods Sold
=25.896 - 0.576
=25.32

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $86.10 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Adamas Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2021 is calculated as

Gross Margin % (Q: Sep. 2021 )=Gross Profit (Q: Sep. 2021 ) / Revenue (Q: Sep. 2021 )
=(Revenue - Cost of Goods Sold) / Revenue
=25.32 / 25.896
=97.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Adamas Pharmaceuticals  (NAS:ADMS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Adamas Pharmaceuticals had a gross margin of 97.78% for the quarter that ended in Sep. 2021 => Durable competitive advantage


Adamas Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Executives
Vijay Shreedhar officer: Chief Commercial Officer C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss officer: Chief Financial Officer 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson director, 10 percent owner 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee director C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg director 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane officer: Chief Executive Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather officer: Chief Financial Officer
Jennifer J Rhodes officer: CBO, GC & Compliance Officer C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went director, officer: Chief Executive Officer C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni officer: Chief Medical Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301